Antitumor Effects of Cannabidiol, a Nonpsychoactive Cannabinoid, on Human Glioma Cell Lines

  title={Antitumor Effects of Cannabidiol, a Nonpsychoactive Cannabinoid, on Human Glioma Cell Lines},
  author={Paola Massi and Angelo Vaccani and Stefania Ceruti and Arianna Colombo and Maria Pia Abbracchio and Daniela Parolaro},
  journal={Journal of Pharmacology and Experimental Therapeutics},
  pages={838 - 845}
Recently, cannabinoids (CBs) have been shown to possess antitumor properties. Because the psychoactivity of cannabinoid compounds limits their medicinal usage, we undertook the present study to evaluate the in vitro antiproliferative ability of cannabidiol (CBD), a nonpsychoactive cannabinoid compound, on U87 and U373 human glioma cell lines. The addition of CBD to the culture medium led to a dramatic drop of mitochondrial oxidative metabolism [3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H… 

Figures and Tables from this paper

Anti-tumor activity of plant cannabinoids with emphasis on the effect of cannabidiol on human breast carcinoma
∆ 9 -tetrahydrocannabinol (THC) exhibits anti-tumor effects on various cancer cell types, but its use in chemotherapy is limited by its psychotropic activity. We investigated the anti-tumor
Endocannabinoid system and anticancer properties of cannabinoids
Effects of cannabinoids showing low affinity to CB receptors is mediated probably by induction of reactive oxygen species production, and there is a necessity to conduct more experiments to assess the real potential of these compounds.
Novel hexahydrocannabinol analogs as potential anti-cancer agents inhibit cell proliferation and tumor angiogenesis.
Safety and efficacy of a novel cannabinoid chemotherapeutic, KM-233, for the treatment of high-grade glioma
Evidence is provided that KM-233 shows promising efficacy against humanglioma cell lines in both in vitro and in vivo studies, minimal toxicity to healthy cultured brain tissue, and should be considered for definitive preclinical development in animal models of glioma.
The antitumor action of cannabinoids on glioma tumorigenesis.
This work presents the available experimental and clinical data, to date, regarding the antitumor action of cannabinoids on the tumorigenesis of gliomas.
Cannabidiol as potential anticancer drug
The present review will focus on the efficacy of CBD in the modulation of different steps of tumourigenesis in several types of cancer and highlights the importance of exploring CBD/CBD analogues as alternative therapeutic agents.
Cannabinoids: potential antitumoral agents?
The fair safety profile of THC, together with its possible growth-inhibiting action on tumor cells, may set the basis for future trials aimed at evaluating the potential antitumoral activity of cannabinoids.
Anti-Cancer Potential of Cannabinoids, Terpenes, and Flavonoids Present in Cannabis
The potential anti-cancer effects of cannabinoids, terpenes and flavonoids, present in cannabis, are explored in this literature review.
Structure–Effect Relationships of Novel Semi-Synthetic Cannabinoid Derivatives
Background: As a library of cannabinoid (CB) derivatives with (-)-trans-cannabidiol (CBD) or (-)-trans-cannabidivarin (CBDV) scaffold, we synthesized nine novel cannabinoids: 2-hydroxyethyl
Glioblastoma: Anti-tumor Action of Natural and Synthetic Cannabinoids
The good safety profile observed in a pilot clinical trial, together with remarkable anti-tumor effects reported in preclinical studies may set the basis for further research aimed at better evaluation of the potential anti-cancer activity of cannabinoids.


Evidence for Cannabinoid Receptor-Dependent and -Independent Mechanisms of Action in Leukocytes
The demonstration that cannabinoid-induced inhibition of PMA/Io-stimulated interleukin-2 was not mediated via CB1 or CB2 is suggested, which suggests that immune modulation produced by cannabinoids involves multiple mechanisms, which might be both cannabinoid receptor-dependent and -independent.
Inhibition of rat C6 glioma cell proliferation by endogenous and synthetic cannabinoids. Relative involvement of cannabinoid and vanilloid receptors.
The antiproliferative effects of the endocannabinoids upon C6 cells are brought about by a mechanism involving combined activation of both vanilloid receptors and to a lesser extent cannabinoid receptors, and leading to oxidative stress and calpain activation.
Inhibition of glioma growth in vivo by selective activation of the CB(2) cannabinoid receptor.
It is shown that local administration of the selective CB(2) agonist JWH-133 at 50 microg/day to Rag-2(-/-) mice induced a considerable regression of malignant tumors generated by inoculation of C6 glioma cells, and showed that selective activation of the CB( 2) receptor signaled apoptosis via enhanced ceramide synthesis de novo.
Molecular targets for cannabidiol and its synthetic analogues: effect on vanilloid VR1 receptors and on the cellular uptake and enzymatic hydrolysis of anandamide
Results suggest that VR1 receptors, or increased levels of endogenous AEA, might mediate some of the pharmacological effects of CBD and its analogues, and (−)‐5′‐DMH‐CBD represents a valuable candidate for further investigation as inhibitor of AEA uptake and a possible new therapeutic agent.
Anti-tumoral action of cannabinoids: Involvement of sustained ceramide accumulation and extracellular signal-regulated kinase activation
It is shown that intratumoral administration of Δ9-tetrahydrocannabinol and the synthetic cannabinoid agonist WIN-55,212-2 induced a considerable regression of malignant gliomas in Wistar rats and in mice deficient in recombination activating gene 2.
Antineoplastic activity of cannabinoids.
Delta9-THC administered orally daily until death in doses of 50, 100, or 200 mg/kg did not increase the life-spans of (C57BL/6 times DBA/2)F1 (BDF1) mice hosting the L1210 murine leukemia, however, delta9- THC administered daily for 10 days significantly inhibited Friend leukemia virus-induced splenomegaly.
D-9-Tetrahydrocannabinol Inhibits Antitumor Immunity by a CB2 Receptor-Mediated, Cytokine-Dependent Pathway
D-9-tetrahydrocannabinol (THC), the major psychoactive component of marijuana, suppresses host immune reactivity against lung cancer by inhibiting antitumor immunity by a CB2 receptor-mediated, cytokine-dependent pathway.
Anandamide induces cell death independently of cannabinoid receptors or vanilloid receptor 1: possible involvement of lipid rafts
In contrast, methyl-β cyclodextrin (MCD), a membrane cholesterol depletor, completely blocked anandamide-induced cell death in a variety of cells, including PC12, C6, Neuro-2a, CHO, HEK, SMC, Jurkat and HL-60 cells, implying a novel role for of membrane lipid rafts in an andamide- induced cell death.